Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

2.

Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.

Lane SR, Nanda P, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, Jurisson SS, Smith CJ.

Nucl Med Biol. 2010 Oct;37(7):751-61. doi: 10.1016/j.nucmedbio.2010.04.016.

PMID:
20870150
3.

Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.

Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.

Nucl Med Biol. 2014 Apr;41(4):355-63. doi: 10.1016/j.nucmedbio.2014.01.001.

4.

64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.

Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.

Nucl Med Biol. 2012 Apr;39(3):377-87. doi: 10.1016/j.nucmedbio.2011.10.004.

5.

Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14).

Fournier P, Dumulon-Perreault V, Ait-Mohand S, Tremblay S, Bénard F, Lecomte R, Guérin B.

Bioconjug Chem. 2012 Aug 15;23(8):1687-93. doi: 10.1021/bc3002437.

PMID:
22770480
6.

Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.

Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Bénard F, Guérin B.

Bioconjug Chem. 2011 Aug 17;22(8):1729-35. doi: 10.1021/bc2002665.

PMID:
21761921
7.

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.

J Nucl Med. 2007 Aug;48(8):1327-37.

8.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005.

PMID:
23969085
9.

Synthesis and radiopharmacological evaluation of ⁶⁴Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator.

Bergmann R, Ruffani A, Graham B, Spiccia L, Steinbach J, Pietzsch J, Stephan H.

Eur J Med Chem. 2013;70:434-46. doi: 10.1016/j.ejmech.2013.10.013.

PMID:
24184988
10.
11.

(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Liu Z, Yan Y, Liu S, Wang F, Chen X.

Bioconjug Chem. 2009 May 20;20(5):1016-25. doi: 10.1021/bc9000245.

12.

microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.

Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.

J Nucl Med. 2004 Aug;45(8):1390-7.

13.

Bombesin analogues for gastrin-releasing peptide receptor imaging.

Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Smith CJ.

Nucl Med Biol. 2012 May;39(4):461-71. doi: 10.1016/j.nucmedbio.2011.10.009.

PMID:
22261143
14.

The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.

Varasteh Z, Mitran B, Rosenström U, Velikyan I, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.

Nucl Med Biol. 2015 May;42(5):446-54. doi: 10.1016/j.nucmedbio.2014.12.009.

PMID:
25684649
15.

In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.

Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.

J Nucl Med. 2011 Mar;52(3):470-7. doi: 10.2967/jnumed.110.082826.

16.
17.

In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.

Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V, Orlova A.

PLoS One. 2013 Dec 3;8(12):e81932. doi: 10.1371/journal.pone.0081932.

18.

PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.

Dijkgraaf I, Franssen GM, McBride WJ, D'Souza CA, Laverman P, Smith CJ, Goldenberg DM, Oyen WJ, Boerman OC.

J Nucl Med. 2012 Jun;53(6):947-52. doi: 10.2967/jnumed.111.100891.

19.

PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.

Jamous M, Tamma ML, Gourni E, Waser B, Reubi JC, Maecke HR, Mansi R.

Nucl Med Biol. 2014 Jul;41(6):464-70. doi: 10.1016/j.nucmedbio.2014.03.014.

PMID:
24780298
20.

Supplemental Content

Support Center